US Material Events SEC 8-K Filings — October 19, 2026

19-10-2026

OpenWorld, Inc. (NASDAQ: OPNW), which filed this Exhibit 99.1 press release under VerifyMe, Inc. (VRME) per the submitted metadata, announced the signing of a definitive merger agreement to acquire Blocksight Holdings Co., an AI-agent platform for tokenizing real-world assets, intended to serve as the operating layer for its tokenized financing programs. The company also disclosed two non-binding term sheets: a BeyondAI IP-backed transaction of up to $130 million (October 7, 2026) and a Meridian tokenized solar/AI computing program of up to $1 billion (October 15, 2026). All three transactions remain subject to due diligence, documentation, and closing conditions, and there is no assurance any will be consummated.

• · Blocksight acquisition was first announced October 1, 2026; this release reports signing of the definitive merger agreement.
• · Meridian program targets initial installations beginning Q4 2026, with first commercial site targeted for Q1 2027.
• · Meridian would own the storage assets within the structure, and Meridian holds purchase rights to Tesla Powerwall systems.
• · BeyondAI transaction is a financing backed by IP rights; BeyondAI retains control of its technology.
• · Blocksight co-founders Patrick Kim and Peter Hong are expected to join OpenWorld upon merger closing.
• · Risk factors flagged include possible Board non-approval, failure to close, litigation, tokenized securities regulatory scrutiny, and integration risk.

19-10-2026

Agassi Sports Entertainment Corp. (AASP) disclosed that its $1,000,000 Convertible Promissory Note held by Investments AKA, LLC, an entity controlled by largest beneficial stockholder Andre Agassi, was converted on October 16, 2026 into 200,000 common shares and 200,000 warrants at $5.00 per unit, with no accrued interest outstanding. In a related transaction, Investments AKA separately purchased 300,000 units for $1,500,000, and two accredited investors bought 65,000 units for $325,000 in private placements, dilutive to existing holders. The company will have 13,711,824 shares outstanding after the Note Shares and Subscription Shares are issued, and the transactions involve a related party whose CFO is also the Company's CFO.

• · Convertible Note was originally due July 27, 2027 and would only auto-convert in a Next Equity Financing of at least $3,000,000; the October 2026 amendment converted it early at $5.00 per unit, below the $7.00 warrant exercise price.
• · Investments AKA's accrued interest was forgiven upon conversion, a related-party concession the company did not quantify.
• · Subscription Agreement and Investor Subscription Agreements include piggy-back registration rights for two years on Note Shares, Subscription Shares and Investor Shares.
• · Investor Warrants carry a 4.999% ownership blocker, which can be raised to 9.999% on 61 days' written notice.
• · Exhibit 10.3 references 'Unit Subscription Agreement'; the Item 9.01 exhibit list contains an apparent typo ('Offering Warrants') in the Item 3.02 share-count section, which should refer to Subscription Warrants.

19-10-2026

American Clean Resources Group, Inc. (ACRG) appointed Anthony Evers as Fractional Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer effective October 19, 2026, replacing Tawana Bain as Interim Principal Financial Officer and Interim Principal Accounting Officer. Evers will serve under a consulting agreement with Satevers II LLC at $250 per hour (up to 60 billable hours per month), rising to $275 per hour from day 91 unless a fixed monthly retainer is agreed. The filing discloses no financial results and no negative or flat performance metrics.

• · Evers previously served as CFO and COO of SurgePays, Inc. from 2020, with that employment ending December 31, 2025, and provided consulting services to SurgePays through June 30, 2026
• · Evers' consulting services cover financial reporting, SEC filings, and transition assistance
• · The Consulting Agreement will be filed as an exhibit to the Form 10-K for fiscal year ending December 31, 2026
• · No family relationships, no selection arrangements, and no Item 404(a) related-party interest beyond the Consulting Agreement

19-10-2026

iBio, Inc. filed a Certificate of Amendment to its Certificate of Incorporation, executed October 16, 2026 by CEO and CSO Martin Brenner, restating the first sentence of Article Fourth to authorize 501,000,000 total shares of capital stock (500,000,000 common and 1,000,000 preferred, each at $0.001 par value). The amendment was approved by the Board and adopted by stockholders under DGCL Section 242 and becomes effective upon filing with the Delaware Secretary of State. The exhibit itself contains no details on the number of shares currently outstanding, the purpose of the increase, or any financing transaction, so its investor impact cannot be fully assessed from this document alone.

• · Amendment executed October 16, 2026, and effective upon filing with the Delaware Secretary of State
• · Approved by the Board of Directors and adopted by stockholders at a meeting under DGCL Section 242
• · Certificate of Incorporation history includes multiple prior amendments and preferred stock designations (Series A, B, C, and 2022 Convertible Preferred), with the most recent prior amendment filed November 28, 2023

19-10-2026

Cambium Networks, Ltd. (In Administration), the UK subsidiary of Cambium Networks Corp (CMBM), entered into a Business Sale Agreement dated October 14, 2026 with Univastu UK Limited to sell its business as a going concern and related assets, following the appointment of joint administrators from RSM UK Restructuring Advisory LLP on September 14, 2026. The sale covers the Specified Products (including ePMP, PTP550, PON fiber, cnRanger, Wi-Fi access points, switch products, and Network Security Edge products), while fixed broadband and defence product lines (PMP450, PTP 820/850, cnWave, cnMaestro, and others) are excluded. The filing does not disclose the purchase price in the excerpt provided.

• · Administrators were appointed on September 14, 2026 under paragraph 22 of Schedule B1 to the Insolvency Act 1986, indicating the UK entity is insolvent
• · The sale is structured as a going concern transfer covering business intellectual property, customer and supplier contracts, employees (TUPE transfers), stock, plant and machinery, and book debts
• · Excluded Assets and Excluded Products (fixed broadband and defence lines) are carved out of the sale and remain with the Seller or its affiliates
• · A Licence Agreement and transition services agreement with Airspan Communications Limited, both dated September 22, 2026, are annexed as Schedule 12 as Defence Sale Contracts
• · Buyer warranties, administrators' liability limits, and no-recourse protections for Vector Capital related persons are included, limiting recourse against sellers and administrators
• · The filing includes Items 1.01 (Material Definitive Agreement), 2.01 (Completion of Acquisition or Disposition of Assets), and 9.01 (Financial Statements and Exhibits)

19-10-2026

Astrotech Corporation (ASTC) approved on October 13, 2026 a Transaction Incentive Bonus Plan for its wholly-owned subsidiary 1st Detect Corporation, funding a bonus pool equal to 20% of net Sale Transaction proceeds, but only if transaction value reaches at least $20 million. The Board also approved a First Amendment removing the sale of a major subsidiary from the 'Qualifying Transaction' definition of the Company's existing Transaction Bonus Plan. No financial results or cash outlays are disclosed at this stage, and the filing contains no quantified performance comparisons.

• · Bonus payments are due on or within 30 days after Sale Transaction proceeds are received, and eligibility is forfeited on termination of employment or failure to timely return a release.
• · Unallocated pool amounts may be awarded to CEO Thomas B. Pickens III at the discretion of Tom Wilkinson, if Wilkinson remains an independent director and administrator at the time of a sale.
• · Award letters for both plans are filed as Exhibits 10.3 and 10.4; the amended Company plan is filed as Exhibit 10.2.

19-10-2026

Chord Energy provided preliminary 3Q26 operational and financial results, with volumes exceeding the high end of guidance across oil, natural gas and NGLs and CapEx in line with guidance, driving adjusted free cash flow above expectations. The company repurchased $205MM of shares in 3Q26 at an average of $135.74/share and another $44.3MM quarter-to-date in 4Q26, and announced the divestiture of non-operated Marcellus assets for $550MM gross consideration. Results are unaudited and the condensed consolidated financial statements are not yet available; the company also reported a $48.7MM loss on realized hedges in 3Q26.

• · Average realized commodity prices in 3Q26: NYMEX WTI averaged $85.69/Bbl and NYMEX Henry Hub averaged $2.96/MMBtu
• · Share repurchases averaged $135.74/share in 3Q26 and $142.32/share quarter-to-date in 4Q26
• · Preliminary 3Q26 financial data is unaudited and not reviewed by the independent auditor; actual results could differ materially
• · Marcellus-related CapEx exceeded internal expectations by about $6MM, partly offset by reimbursable non-op CapEx
• · Results compared against guidance released in August 2026

19-10-2026

Venu Holding Corporation (NYSE American: VENU) disclosed that President William Hodgson will cease serving as President effective October 13, 2026, remaining an employee until December 1, 2026 with severance payable over a 90-day period (final terms not yet determined); no successor has been named. The company also completed Aramark's additional $10,005,000 Series B Preferred equity investment on October 15, 2026, and reduced the principal of its $25,000,000 senior secured convertible debenture to $12,500,000 by applying the $12,500,000 holdback, which cut each remaining monthly installment principal from $5,000,000 to $2,500,000 and reduced the Investor Warrants from 1,000,000 to 500,000 shares and Placement Agent Warrants from 200,000 to 100,000 shares. The first installment of $2,875,000 was paid in cash on October 14, 2026.

• · Hodgson's departure was mutual and not the result of any disagreement on company policies or practices
• · No designated successor named; presidential responsibilities shifted to current management and recently added content procurement personnel
• · Holdback application was made because the company determined its financing needs no longer required the $12.5M, reducing debt service, payment premiums, and warrant dilution
• · Remaining installments are expected to be paid in cash on their due dates

19-10-2026

Tamboran Resources Corporation announced that Todd Abbott has been appointed Managing Director in addition to his existing role as Chief Executive Officer, effective October 19, 2026. The appointment formalizes his board-level leadership as the company moves from appraisal into development of the Beetaloo Basin, with first gas sales to the Northern Territory market achieved in recent months. The material terms of his appointment are unchanged from the ASX announcement of January 12, 2026.

• · Abbott was first appointed CEO in January 2026, and this filing formalizes his Board-level role as Managing Director
• · Tamboran achieved first gas sales from the Beetaloo to the Northern Territory gas market in the months preceding the announcement
• · Company guidance noted in forward-looking disclaimers: no material revenue expected until the second half of 2026, and going-concern doubt raised by recurring operating losses and negative cash flows

19-10-2026

Apogee Acquisition Corp (AACP) disclosed that errors were identified in its unaudited Q2 2026 Form 10-Q (filed August 20, 2026), affecting private placement unit proceeds contributed to the trust account, the number of private placement units, Class A ordinary shares subject to possible redemption, and warrants. On October 14, 2026, the audit committee concluded the previously issued Q2 financials should no longer be relied upon, and a restatement via 10-Q/A is being filed October 16, 2026. The same filing reports that director Anna Brunelle resigned from the Board and its audit and compensation committees, Christopher Valentine was appointed to the audit committee, and COO Tom Watson resigned effective October 14, 2026.

• · Restatement affects Notes 4, 7 and 8 of the Q2 2026 10-Q, covering trust account contributions from private placement unit proceeds, number of private placement units, Class A shares subject to redemption, and warrants
• · Independent registered public accounting firm Adeptus Partners, LLC was consulted on the matters disclosed
• · Company is a Cayman Islands blank check company (SPAC) listed on Nasdaq; emerging growth company status claimed
• · Filing references a 10-Q/A to be concurrently filed October 16, 2026
• · Filing period of report is October 13, 2026; the Form 8-K was signed October 16, 2026

19-10-2026

Omnitek Engineering Corp. disclosed that directors Gary S. Maier and John M. Palumbo resigned from the board effective October 15, 2026. The company states the resignations were not due to any disagreement with the company, its board, attorneys, or auditors on matters relating to operations, policies, or practices. No replacement directors or new officer appointments were disclosed in this filing.

• · Filing reports board resignations effective October 15, 2026, while the filing itself is dated October 19, 2026
• · Company headquarters relocated from 1280 Activity Dr., Vista, California to 1501 N. Carlotte Avenue, Monroe, NC 28110
• · Company is a California corporation with Commission File Number 000-53955 and IRS Employer Identification No. 33-0984450
• · Securities are not registered under Section 12(b); trading symbol listed as N/A

19-10-2026

OS Therapies announced the initial closing of a warrant exercise inducement and exchange offer with nine accredited investors, in which seven holders exercised or pre-funded 5,517,253 shares at a reduced price of $1.30 per share, generating approximately $7.2 million in gross proceeds before solicitation agent fees and offering expenses. The company also disclosed $7 million in accrued refundable U.K. R&D tax credits, expected to be received in early 2027, and reiterated plans to submit regulatory filings for Herlystic™ in the U.S., U.K., EU and Australia in Q4 2026. The offer is scheduled to expire October 30, 2026, and the company's cash runway depends on additional holder participation and the timing of tax credit receipt, so the outcome remains partially uncertain.

• · Offer expires 11:59 p.m. Eastern time on October 30, 2026, unless extended or terminated
• · Most existing warrants exercised by holders carried a $1.40 exercise price, versus the $1.30 offer price
• · Herlystic™ holds ODD, FTD and RPDD from the FDA, and ODD, PRIME and ATMP designations from the EMA
• · Company has completed resubmission of an RMAT designation request and its CNPV letter of intent was accepted by FDA
• · Any PRV received upon BLA approval is intended for sale, with no assurance of receipt or comparable value
• · Securities were issued in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D and are unregistered
• · Herlystic™ Phase 2b trial reported positive results on 12-month EFS primary endpoint and OS secondary endpoint

19-10-2026

ACV Auctions Inc. filed its Twelfth Amended and Restated Certificate of Incorporation (Exhibit 3.1), signed October 16, 2026 by CEO George Chamoun. The restated charter authorizes a single class of Common Stock totaling 1,000 shares at $0.001 par value, retains the existing director and officer exculpation and indemnification provisions, and reserves the right to amend the charter. The exhibit itself contains no transaction-specific financial figures, acquisition price, or deal terms; the Acquisition classification in the preliminary tags is not supported by the exhibit text provided and should be verified against the main 8-K body (Items 2.01 and 5.03 suggest a completed transaction and charter change).

• · Original certificate of incorporation was filed with the Delaware Secretary of State on December 30, 2014
• · Registered agent is Corporation Services Company in Wilmington, Delaware
• · Restated charter adopted under DGCL Sections 242 and 245 and effective upon filing with the Delaware Secretary of State
• · Board is expressly authorized to make, alter, amend or repeal bylaws
• · Director and officer monetary liability exculpation and indemnification provisions carried forward

19-10-2026

Centrus Energy Corp. (NYSE: LEU) announced it acquired Westerman Holdings, LLC, one of its largest suppliers of centrifuge casings and other components, for approximately $116 million ($95 million cash on hand and $21 million equity). The deal is expected to be accretive to adjusted EPS in the first year and to diversify Centrus' revenue base through Westerman's non-nuclear oil and gas and industrial customers. Westerman's CEO Jacob Garrett becomes President of Westerman and a Vice President of Centrus.

• · Westerman was founded in 1909 and has operated for more than a century
• · Centrus acquired all of Westerman's business lines, and Westerman becomes a subsidiary while keeping its brand
• · Barclays was financial advisor to Centrus; Wachtell, Lipton, Rosen & Katz was legal counsel
• · Westerman also serves Marine and other industrial end markets

19-10-2026

ProPetro Holding Corp. (NYSE: PUMP) announced the appointment of Kyle Crowley as an independent director of its Board of Directors, effective October 16, 2026. Crowley brings more than 30 years of power and energy experience, including 21 years at Exelon Corporation, where he led corporate development and executed more than 65 closed transactions with total equity value over $38 billion. The appointment is framed by management as supporting the growth of PROPWR, the company's gas-to-power division, though the release contains no quantitative financial results for the period.

• · Crowley served as SVP, Corporate Finance and Development at Exelon from October 2022 to June 2024, and previously as SVP and Chief Development Officer from December 2010 to October 2022
• · Crowley holds an MBA from the University of Chicago Booth School of Business and a BS in Finance from Indiana University
• · Crowley is a director of ONE Nuclear (NASDAQ: ONEN), serving on its Audit and Compensation Committees
• · Crowley is a director of Hennessy Capital Investment Corp. VIII (NASDAQ: HCIC)
• · Crowley's notable deals include the acquisition of Pepco Holdings, the acquisition of Constellation Energy, and the 2022 spin-off of Constellation Energy Corporation

19-10-2026

The Chefs' Warehouse entered a new $675 million senior secured term loan due October 15, 2033, priced at SOFR plus 2.00%, which refinanced its prior $305 million term loan (repaid for approximately $244.7 million including accrued interest) and funded the redemption of its 2.375% Convertible Senior Notes due 2028. Concurrently, an amendment to its asset-based revolving credit facility conformed covenants to the new term loan and raised the letter of credit sublimit from $50 million to $75 million. Holders of approximately $287.2 million of the Notes converted into cash and 2,671,056 common shares, while the remaining roughly $341,000 was redeemed in cash, so the refinancing reshapes the capital structure with a larger, longer-dated secured debt load and new equity issuance.

• · The new term loan adds roughly $370M of principal over the prior $305M facility, extending maturity from August 2029 to October 2033.
• · The 2.375% convertible notes were largely converted into equity, diluting shareholders by about 2.67 million shares, with cash paid for the cash component of conversions.
• · The ABL amendment loosens the cure period for interest and fee payment defaults from three to five business days.
• · Proceeds were also earmarked for capital expenditures and general corporate purposes, and the full agreements are expected to be filed with the Form 10-Q for the quarter ending September 25, 2026.

19-10-2026

Atkore Inc. (ATKR) filed an 8-K including Exhibit 3.1, its Fifth Amended and Restated Certificate of Incorporation, which sets out corporate governance provisions covering authorized capital, director removal, board by-law authority, director and officer liability limits, and indemnification. The exhibit itself contains no monetary figures, no financial results, and no description of a merger or acquisition, so the preliminary 'Merger/Acquisition' classification is not supported by the excerpt provided. The filing's listed Items (1.02 Termination of Material Agreement, 2.01 Completion of Acquisition or Disposition, 3.01, 3.03, 5.01, 5.02, 5.03) suggest transaction-related activity, but the accompanying narrative text is not included in the content supplied.

• · Authorized capital is 1,000 shares of common stock with $0.01 par value, all voting together as a single class
• · Directors may be removed with or without cause by a majority of outstanding voting shares
• · Board is empowered to make, alter, and repeal the by-laws
• · Officer and director monetary liability is limited except for loyalty breaches, bad faith, intentional misconduct, Section 174 DGCL liability, improper personal benefit, and officer actions brought by or on behalf of the Corporation
• · Mandatory indemnification and advancement of expenses to directors and officers to the fullest extent permitted under DGCL, subject to Board authorization for proceedings they initiate

19-10-2026

Dogwood Therapeutics announced a $5 million private placement to its largest shareholder, a subsidiary of CK Life Sciences Int'l. (Holdings) Inc. (CKLS), issuing 4,098,360 shares of common stock at $1.22 per share with no warrants attached. The company says the proceeds will fund Phase 3 preparatory activities for Halneuron® and working capital, extending runway through March 2027, while topline data from the Phase 2b HAL-CINP trial is expected in November 2026. The placement is expected to close on or before October 29, 2026, and the filing carries no disclosed negative performance metrics.

• · Shares priced at $1.22 per share, at-the-market under Nasdaq rules, with no warrants or derivative securities included
• · Private placement made under Section 4(a)(2) of the Securities Act / Regulation D, so shares are unregistered and restricted
• · Expected close on or before October 29, 2026
• · Halneuron® holds FDA Fast Track designation for chemotherapy-induced neuropathic pain (CINP)
• · SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute
• · CKLS is listed on the Hong Kong Stock Exchange (Stock Code: 0775) and is the company's largest shareholder

19-10-2026

TCGX Acquisition Corp., a Nasdaq-listed SPAC, and clinical-stage biotech TriGemX Bio announced a definitive business combination agreement that will take TriGemX public as TriGemX Bio, Inc. (ticker TGEM). The deal is expected to deliver approximately $246 million in gross proceeds, including a concurrent $160 million PIPE at $10.00 per share and roughly $86 million from the SPAC trust assuming no redemptions, with a post-transaction equity value of about $600 million and closing expected in Q1 2027. Proceeds are intended to fund the Phase 3 program for elismetrep in acute migraine, a migraine-prevention trial, and commercial readiness, though completion depends on shareholder approvals and customary conditions, and no assurance is given the deal will close on the stated terms.

• · Elismetrep Phase 3 results for the acute migraine trial are anticipated in mid-2027
• · Two pivotal Phase 3 studies (NCT07645924 and NCT07816367) and a long-term safety study (NCT07674654) are underway
• · Combined Company will trade on Nasdaq under the new ticker TGEM and domesticate as a Delaware corporation
• · Transaction requires approval of both TCGX shareholders and TriGemX stockholders and an S-4 registration statement will be filed
• · Elismetrep is investigational and has not been approved by the FDA or any other regulator

19-10-2026

Tradeweb Markets (Nasdaq: TW) has entered into a definitive agreement to acquire Trumid Holdings, LLC, an electronic credit trading marketplace, for a total purchase price of approximately $1.97 billion, comprised of $1.75 billion for the business and approximately $220 million for tax assets (net present value at a 7% discount rate). Consideration consists of about $1.89 billion in cash, funded primarily from cash on hand, and $82 million in equity. The deal was unanimously approved by both boards, is subject to customary closing conditions including regulatory approvals, and is targeted to close in the first half of 2027. Management expects it to be accretive to adjusted EPS within the first full year after closing, with accretion rising as expense synergies are realized.

• · Transaction creates a single platform spanning trade inception through the secondary market, extending Tradeweb into grey markets and new issue trading
• · Trumid focuses on U.S. dollar-denominated Investment Grade, High Yield, Distressed, and Emerging Market bonds, with a strong hedge fund and systematic participant footprint
• · Tradeweb plans to add automation and AI-enabled trade decisioning tools and expanded data and analytics to the combined protocol ecosystem
• · Tradeweb's Q3 2026 financial results are scheduled for October 29, 2026, with a conference call at 9:30 AM EDT; a deal-specific call is set for October 20, 2026 at 8:30 AM EDT
• · Morgan Stanley is exclusive financial advisor to Tradeweb; Goldman Sachs is exclusive financial advisor to Trumid

19-10-2026

Treasure Global Inc (TGL) entered into a Brand Mastery & Market Development Consultancy Agreement on October 15, 2026 with PEPE CEMERLANG MARKETING, a Malaysian marketing firm, for brand strategy, identity development, and marketing execution across three phases over an 18-month term. The total Service Fee is USD 2,000,000, payable in milestones that the Company may settle in cash, in restricted Shares, or a combination of both at its sole discretion. The filing discloses no revenue, earnings, or other operating results for the period, so no period-over-period comparison is available.

• · The Company may settle milestone payments in Shares priced at the last Nasdaq closing price on the trading day before its election notice, which creates potential dilution for existing shareholders.
• · Item 3.02 discloses the Company's right to issue unregistered Shares to the Consultant as payment, a separate equity-issuance disclosure under the Securities Act.
• · The Agreement is non-exclusive, the Consultant does not guarantee any commercial outcome, and the Company may engage other consultants.
• · Disputes are governed by Malaysian law with exclusive jurisdiction in Malaysian courts after a 30-day good-faith consultation period.
• · The filing does not disclose the Company's financial condition, cash position, or whether the USD 2.0M fee is material relative to its resources.

19-10-2026

RMCF reported fiscal Q2 2027 results with total revenue of $6.7M (vs. $6.8M, down ~2.5% YoY) and a net loss of $1.3M ($(0.14)/share) versus a $0.7M loss a year earlier, while gross margin improved to 8.0% from (0.6)%. The Board formed a strategic committee exploring alternatives including a possible sale, merger, or going-private transaction, and the company received third-party expressions of interest. Subsequent events include a $6.6M sale-leaseback of the Durango facility, repayment of $6.6M of 12% debt, and a new $2.0M Alpine Bank loan, while cash fell to $416K and current liabilities rose sharply to $13.6M.

• · Net loss for six months nearly tripled to $2.4M from $1.0M, with six-month revenue down 3.3%.
• · Cash fell to $416K from $1.2M, while notes payable were reclassified to current ($6.8M), driving current liabilities to $13.6M, a near doubling since February 2026.
• · Stockholders' equity declined 42% to $3.0M from $5.2M since fiscal year-end, with accumulated deficit widening to $12.4M.
• · Franchise and royalty fees fell 18% YoY to $1.3M, a key drag on revenue despite higher retail sales.
• · Retail operating expenses nearly doubled YoY and G&A rose 36%, reflecting the larger company-owned store base and higher corporate costs.
• · Going-concern language is referenced in the forward-looking statements ("ability to continue as a going concern"), signaling liquidity risk.
• · The company received expressions of interest from third parties in the strategic review, but there is no assurance any transaction will occur.
• · Filing refers to a Form 10-Q for additional detail on the subsequent-event transactions.

19-10-2026

Globaltek Ventures, Inc. filed this Form 8-K (Items 4.01 and 4.02 related) to disclose that it has engaged Bansal & Co LLP as its independent registered public accounting firm to review interim financial statements for the six months ended June 30, 2026. The engagement terminates upon completion of that review. The filing states there were no disagreements or reportable events with the prior accountant during fiscal 2024, fiscal 2025, or the interim period through October 15, 2026, and it is signed by Jacob Sherman as Custodian.

• · Bansal & Co LLP's engagement is limited to reviewing interim financial statements for the six months ended June 30, 2026, and terminates on completion of that review.
• · Engagement date referenced as October 15, 2026, with a related prior Form 8-K dated October 14, 2026 and filed October 15, 2026.
• · Filing is signed by Jacob Sherman as Custodian, which raises governance questions given the company's custodianship status.
• · The filing is a self-described Globaltek Ventures, Inc. document, but the submitted metadata identifies the registrant as Ameritek Ventures, Inc. (ATVK); this discrepancy should be verified against EDGAR before publication.

19-10-2026

Ford Credit Floorplan Master Owner Trust A filed an 8-K reporting entry into Transaction Documents in connection with the issuance of asset-backed Notes described in the October 6, 2026 Prospectus. The filing discloses two exhibits: a Series 2026-3 Indenture Supplement dated October 1, 2026 with the Indenture Trustee, and a Series 2026-3 Account Control Agreement with The Bank of New York Mellon. The filing contains no dollar amounts, note balances, or pricing terms.

• · Date of earliest reported event: October 16, 2026; filing dated October 19, 2026
• · Prospectus dated October 6, 2026, filed under Rule 424(b)(2)
• · Indenture Supplement (Exhibit 4.2) dated as of October 1, 2026, between the Trust and the Indenture Trustee
• · Account Control Agreement (Exhibit 10.15) dated as of October 1, 2026, between the Trust and The Bank of New York Mellon

19-10-2026

Nexentis Technologies Inc. (Nasdaq: NXTS) issued a total of approximately 922,188 shares of common stock on October 15, 2026, comprising grants under its 2022 Share Incentive Plan to the CEO (101,549 shares), CFO (51,000 shares), directors (208,639 shares in aggregate), and a consultant for accounting services (51,000 shares), plus 510,000 shares issued outside the Plan to consultants for financial, investor relations, and business development services. The issuances were made in reliance on the Section 4(a)(2) private placement exemption, and the filing reflects an equity-based compensation and consultant payment activity rather than a change in leadership.

• · Filing is dated October 19, 2026 and reports events effective October 15, 2026, under Items 3.02 and 5.02
• · Shares were issued in reliance on Section 4(a)(2) of the Securities Act of 1933 as transactions not involving a public offering
• · Company is an emerging growth company and common stock trades under symbol NXTS
• · Filing notes the registrant's principal executive offices are in Ness Ziona, Israel and the registrant is incorporated in Nevada

19-10-2026

Vaxart, Inc. (OTCQB: VXRT) appointed Vice Admiral Raquel "Rocky" C. Bono, M.D. (U.S. Navy, Ret.) to its Board of Directors on October 19, 2026, pursuant to a cooperation agreement with a group of stockholders entered into in July 2026. Dr. Bono will chair the Stockholder Engagement Committee and serve on the Nominating and Governance and Clinical and Regulatory Affairs Committees. The filing discloses no financial results, so no period-over-period performance metrics are reported.

• · Dr. Bono is a board-certified trauma surgeon who previously served as Director of the Defense Health Agency and as Director of Washington State's Pandemic Health System Response.
• · Dr. Bono currently serves on the board of Humana Inc. (NYSE: HUM) and is Managing Partner of NAVA Edge LLC.
• · Vaxart's Lead Independent Director described the company as making progress toward a series of value-inflection milestones.
• · Vaxart's stock is quoted on the OTCQB, not a major exchange.

19-10-2026

Torrid Holdings Inc. (NYSE: CURV) announced that Chief Financial Officer Paula Dempsey has resigned to pursue another opportunity, and she will remain in the role through mid-November 2026 to ensure a smooth transition. The company appointed Will Langley, former CFO of Belk (January 2020 to May 2025) with 20 years of experience at Belk, as Interim Chief Financial Officer effective October 28, 2026. The filing contains no quantitative financial results, so no performance metrics are reported.

• · Dempsey's departure is effective with service continuing through mid-November 2026.
• · Langley's interim appointment takes effect October 28, 2026, which leaves a gap between Dempsey's stated end date and his start date only if the transition overlaps; the filing does not specify whether the roles overlap.
• · Dempsey is credited with leading store optimization efforts and with disciplined capital allocation and expense management.
• · The filing states Dempsey resigned to pursue another opportunity, without naming the new employer.
• · The filing describes the appointment as interim, so a permanent CFO search is implied but not confirmed.

19-10-2026

Glucotrack, Inc. entered into a Waiver Agreement on October 13, 2026 with holders of warrants issued under its July 14, 2026 Securities Purchase Agreement, waiving a restriction on issuing common stock or equivalents (until 90 days after registration statement effectiveness and stockholder approval) and an exercise price adjustment tied to variable rate transactions. In consideration, the Company is obligated to issue new warrants to purchase 406,198 shares at $7.50 per share, expiring in five years, which are not exercisable until stockholder approval under Nasdaq Listing Rule 5635 is obtained. The waiver is a dilution-related concession that the Company made to secure flexibility, with the new warrant overhang representing a potential future dilution event.

• · Waiver is effective as to all Holders for the issuance restriction (Section 5.10(a)), but effective only for Holders who executed it for the exercise price adjustment (Section 3(e)) under Section 5(m) of the Existing Warrants
• · Waiver was executed by Requisite Holders as required by Section 11.9 of the Purchase Agreement
• · New Warrants are issued in reliance on Section 4(a)(2) of the Securities Act (private placement exemption)
• · Exhibits filed: Form of New Warrant (Exhibit 4.1) and Form of Waiver Agreement (Exhibit 10.1)

19-10-2026

Enerpac Tool Group Corp. (EPAC) entered into an Amended and Restated Credit Agreement dated as of October 16, 2026, with PNC Bank, National Association as Administrative Agent, providing a $550 million revolving credit facility and a $300 million term loan facility. The agreement amends and restates the existing credit agreement dated September 9, 2022 (as amended by a First Amendment dated July 7, 2026), with Enerpac Tool Group Corp., Enerpac Finance Limited, and ATU Euro Finance B.V. as initial borrowers. The filing is a refinancing and restructuring of existing debt rather than a reported change in operating performance, and the exhibit excerpt contains no period-over-period financial results.

• · The agreement is dated October 16, 2026 and amends and restates the Credit Agreement dated September 9, 2022
• · Enerpac Finance Limited is an England and Wales company (company number 05825819); ATU Euro Finance B.V. is a Dutch entity seated in Ede, Netherlands
• · PNC Bank, National Association acts as Administrative Agent, Swingline Loan Lender and an Issuing Lender
• · Five additional institutions serve as Joint Lead Arrangers and Joint Bookrunners
• · The filing includes Items 1.01 (Material Agreement), 2.03 (Creation of a Direct Financial Obligation) and 9.01 (Financial Statements and Exhibits)
• · Excerpt includes covenants on indebtedness, liens, and a maximum net leverage ratio (Section 9.13), with an 'Acquisition Holiday' concept referenced

19-10-2026

Tempest Therapeutics (Nasdaq: TPST) appointed John W. Frederick to its board of directors, announced October 14, 2026 and filed under Item 5.02. Frederick brings more than three decades of finance, capital markets and operations experience, most recently as CFO of Skillsoft, and the company says his expertise will support disciplined capital deployment and its in vivo CAR-T development milestones. The filing contains no financial results or quantitative performance data, so no period-over-period comparison is possible.

• · Frederick previously served as Chief Financial Officer of Skillsoft, responsible for financial reporting, investor relations, capital markets and liquidity strategy
• · Frederick also served at Indigo Ag as CFO and Global Head of Carbon Commercial Operations, and as Chief Operating and Financial Officer of Snagajob
• · Frederick currently serves on the board of MutualOne Bank and has served on the board of SenSanna, Inc. since 2016
• · Frederick holds a B.A. in Economics from the University of Maryland
• · Filing includes Item 9.01 exhibits (press release Exhibit 99.1) and Item 7.01 Regulation FD disclosure

19-10-2026

Polomar Health Services, Inc. (PMHS) disclosed that directors Alexandra Peterson (Audit Committee) and Gabrielle Toledano (Compensation Committee) resigned effective October 14, 2026, with no disagreement cited. The Board reduced its size from five to three directors (George Hornig, George Caruolo, Gabriel Del Virginia) and has not yet decided whether to fill the vacancies or further reduce the Board.

• · Both resignations were notified to the Board on October 15, 2026, effective October 14, 2026.
• · Ms. Peterson's departure leaves the Audit Committee and Ms. Toledano's departure leaves the Compensation Committee without those members, raising committee composition questions.
• · The Company states neither resignation resulted from a disagreement on operations, policies, or practices.
• · The Company's principal executive office moved from Palm Harbor, FL to New York, NY (575 Lexington Avenue), with a current telephone area code of (727).

19-10-2026

Collegium Pharmaceutical, Inc. (COLL) filed an 8-K dated October 19, 2026, disclosing under Item 1.02 (Termination of a Material Definitive Agreement) an event dated October 15, 2026. The filing excerpt provided contains only the signature block and a reference to a prior quarterly report, so the specific agreement terminated, its counterparty, and the financial terms cannot be determined from the content supplied.

• · Event date of October 15, 2026, with the 8-K filed October 19, 2026
• · Item 1.02 indicates termination of a material definitive agreement
• · Filing signed by CFO Colleen Tupper

19-10-2026

ZoomInfo Technologies entered a memorandum of understanding on October 16, 2026 to settle the securities class action filed in September 2024 (class period November 10, 2020 to August 5, 2024), agreeing to pay the putative class $44 million, a portion of which is expected to be covered by remaining insurance funds. The settlement is subject to court approval and is not an admission of wrongdoing, but it does not resolve related shareholder derivative suits, a direct opt-out action, or a separate putative class action filed June 25, 2026, all of which remain ongoing and will be vigorously defended.

• · Securities Litigation was filed September 4, 2024 in the U.S. District Court for the Western District of Washington, alleging misleading statements including about COVID-19 pandemic effects on performance
• · Settlement remains subject to preliminary and final court approval and other conditions; the company flags risks including failure to execute a definitive stipulation, higher-than-expected expense, objections or appeals, and expansion of the class after confirmatory discovery
• · Unresolved matters include shareholder derivative suits in the Washington District Court and Delaware Court of Chancery, a direct opt-out action, and a putative class action filed June 25, 2026 against ZoomInfo and certain current officers

19-10-2026

Vail Resorts, Inc. disclosed that on October 16, 2026, its subsidiary Vail Holdings, Inc. and the Company, as guarantors, entered into a First Amendment to the Tenth Amended and Restated Credit Agreement dated February 9, 2026, with Bank of America, N.A. as administrative agent. The amendment removes the board-composition trigger from the Change of Control Transaction definition and eliminates the administrative agent approval requirement for Financial Hedges, leaving the two voting-equity ownership-based change of control provisions intact.

• · The amended Change of Control Transaction definition no longer treats a majority change in Board composition over any twelve consecutive months as a change of control event.
• · Section 10.8(i) of the Credit Agreement, covering Financial Hedges, no longer requires administrative agent approval for such hedges.
• · The full First Amendment will be filed with the SEC at a later date.

19-10-2026

Acadia Realty Trust (NYSE: AKR) appointed Tamara (Tammy) Fischer as a Trustee and to the Nominating and Corporate Governance Committee, effective October 19, 2026. Fischer brings three decades of REIT financial and executive experience, most recently as Executive Chairperson of National Storage Affiliates Trust until its acquisition by Public Storage in July 2026. The filing is a board appointment announcement with no reported financial results, dividend, or guidance changes.

• · Fischer joins the Nominating and Corporate Governance Committee in addition to the Board
• · Fischer currently sits on the boards of Mid-America Apartment Communities (since 2023, Audit and Real Estate Investment Committees) and JLL Income Property Trust (since 2023, chairs Audit Committee)
• · Fischer previously was CEO of National Storage Affiliates Trust (January 2020 – March 2023) and CFO of Chateau Communities (1993–2003)
• · Fischer is a certified public accountant (inactive) with a B.A. in Business Administration from Case Western Reserve University

19-10-2026

CarMax appointed Darren W. Woodell, currently Vice President and Controller at Genworth Financial, as Vice President, Controller and Chief Accounting Officer, effective November 11, 2026, succeeding Enrique N. Mayor-Mora as principal accounting officer; Mayor-Mora remains Executive Vice President and Chief Financial Officer. Woodell's offer package includes a $385,000 base salary, a $175,000 corporate bonus payable May 2027, a $100,000 sign-on bonus, and $330,000 in stock-settled RSUs vesting on the third anniversary of grant. The filing reports no financial results, so the news is a routine leadership transition with no reported negative or positive performance metrics.

• · Woodell has been Vice President and Controller (Principal Accounting Officer) at Genworth since February 2024, and has been with Genworth since 2010
• · Woodell is a licensed Certified Public Accountant in Virginia and Florida
• · Woodell's sign-on bonus and RSU grant are part of his offer letter terms
• · Woodell has no family relationships with directors or executive officers and no material related-party interest under Item 404(a)

19-10-2026

Once Upon a Farm, PBC (NYSE: OFRM) announced the appointment of Scott Morris, Co-Founder of Freshpet, to its Board of Directors effective immediately (October 19, 2026). Morris brings more than three decades of consumer packaged goods experience, including co-founding Freshpet in 2006 and building it into a category leader with more than $1 billion in annual sales. The filing is a board appointment press release with no financial results, guidance, or quantitative performance data disclosed.

• · Morris previously served as President, Chief Operating Officer and Chief Marketing Officer at Freshpet and was instrumental in building its in-store refrigerated network
• · Morris also served as Vice President of Marketing at The Meow Mix Company and spent more than a decade in sales and marketing leadership at Ralston Purina
• · Morris is an existing acquaintance of CEO John Foraker, per the company's statement

19-10-2026

Old Second Bancorp's Vice Chairman Gary Collins notified the company on October 14, 2026 of his decision to retire effective October 31, 2026, and will also resign from the boards of the Company and Old Second National Bank on his termination date. The retirement was not due to any disagreement with the company, and Mr. Collins has entered into a Separation and General Release Agreement providing approximately $211,150 in lump-sum cash payments, full vesting of unvested time-based RSUs, and pro-rata vesting (at target) of performance-based RSUs, subject to a release of claims.

• · Retirement effective October 31, 2026; Collins resigns from both boards upon termination of employment
• · Separation payments are conditional on execution and non-revocation of a release of claims
• · Full vesting of unvested time-based RSUs and pro-rata vesting at target of performance-based RSUs
• · Restrictive covenants in Collins' Executive Employment Agreement remain in effect
• · Full Separation Agreement to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026

19-10-2026

CRISPR Therapeutics AG announced that SVP, Finance Andrew J. Silver (age 42) has been promoted to Chief Financial Officer effective immediately, with a $515,000 base salary, a 45% target bonus, and a one-time grant of 25,000 RSUs vesting in full on the second anniversary of grant. Concurrently, CFO Raju Prasad, Ph.D. resigned to pursue external opportunities, stating no disagreement with the Company on financial statements, accounting, or controls, and is expected to remain employed through on or before November 30, 2026.

• · Silver joined CRISPR in October 2018 and previously spent over 10 years at Ernst & Young LLP as a Senior Manager in Assurance Services and is a CPA
• · Silver's employment agreement includes a 6-month notice period on termination without Cause or resignation for Good Reason, extended to 12 months if within 12 months after a Change in Control
• · Prasad's resignation is effective with employment continuing until on or before November 30, 2026, creating a transition window
• · Silver's 2026 bonus will be pro-rated to reflect the effective date of his promotion

19-10-2026

Mobix Labs, Inc. (Nasdaq: MOBX, MOBXW) terminated its Agreement and Plan of Merger with Vision Aerial, Inc., dated July 24, 2026, by written notice delivered October 14, 2026, under Section 8.1(c) following expiration of the contractual termination date. The termination followed delays in due diligence and receipt of financial and accounting information needed to complete the audit, and the transaction was not consummated within the contemplated timeframe. The company describes the termination as amicable and remains open to future opportunities with Vision Aerial.

• · Termination notice delivered October 14, 2026 under Section 8.1(c) of the Merger Agreement dated July 24, 2026
• · The merger agreement had been previously disclosed in an 8-K filed July 29, 2026
• · Delays cited in due diligence and receipt of financial/accounting information required to complete the audit

19-10-2026

Medtronic plc announced on October 15, 2026 the completion of the separation of MiniMed Group, Inc. (Nasdaq: MMED) via an exchange offer in which Medtronic exchanged its entire remaining stake of 252,813,348 MiniMed common shares for outstanding Medtronic ordinary shares. The exchange offer was 5.4x subscribed, and the separation is now complete, with Medtronic retaining no remaining interest in MiniMed. The filing is an 8-K whose Item 5.02 and 5.07 headings (officer/director change and shareholder vote) appear in the filing metadata, but the body text provided contains only the press release exhibit and does not describe any specific officer departure or vote result.

• · Exchange offer results were announced separately on October 14, 2026; the completion release confirms book-entry crediting of MiniMed shares and cash-in-lieu for fractional shares sold in the open market.
• · The separation is intended to be generally tax-free to shareholders for U.S. federal income tax purposes.
• · Goldman Sachs & Co. LLC and BofA Securities, Inc. served as dealer managers for the exchange offer.

19-10-2026

CDW Corporation announced the appointment of Sam Balaji to its Board of Directors, effective October 15, 2026. Balaji, former Global CEO of Consulting & Advisory at Deloitte, brings over three decades of experience in technology, advisory, and global business leadership. The announcement is a governance update with no disclosed financial results, guidance, or quantitative performance data.

• · Balaji currently serves on the board of BlackLine, a financial and accounting cloud software provider, bringing public company governance and cybersecurity oversight experience
• · CDW operates across business, government, education and healthcare sectors in the United States, United Kingdom and Canada

19-10-2026

Integra LifeSciences closed a private offering of $450.0 million of 9.500% senior secured notes due 2033 and amended and restated its credit facility to an overall size of approximately $1.65 billion. The refinancing consists of a $600 million five-year revolver, a $600 million five-year term loan A, and a $450 million seven-year term loan B. Proceeds plus Credit Facility borrowings were used to refinance the existing facility and pay fees and expenses.

• · Notes were offered under Rule 144A to qualified institutional buyers and under Regulation S to non-U.S. persons, and are not registered under the Securities Act
• · Notes are guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the Credit Facility
• · Filing includes Items 1.01, 1.02, and 2.03, covering material agreement entry, termination of the prior credit facility, and creation of a direct financial obligation

19-10-2026

Professional Diversity Network, Inc. (IPDN) disclosed under Item 5.02 that director Shaikh Ali Sultan Al Nuaimi resigned from its Board of Directors, effective October 30, 2026, after notifying the Board on October 16, 2026. He had served as a director since November 2025, and the filing states the resignation was not due to any disagreement with the Company, its management, or the Board regarding operations, policies, or practices.

• · Resignation notice given to the Board on October 16, 2026; effective date October 30, 2026
• · Director had served since November 2025, so tenure was roughly 11 months
• · Filing explicitly states no disagreement with the Company, management, or Board

19-10-2026

Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors effective October 19, 2026, expanding the Board from seven to nine directors. Ms. Peterson joins the Audit Committee as a Class I director and Mr. Coats joins the Compensation Committee as a Class II director; both were granted equity awards under the non-employee director compensation program and entered into the standard indemnification agreement.

• · Ms. Peterson was appointed as a Class I director with a term expiring at the 2027 annual meeting and to the Audit Committee
• · Mr. Coats was appointed as a Class II director with a term expiring at the 2028 annual meeting and to the Compensation Committee
• · The Board determined both new directors meet Nasdaq independence requirements
• · Neither director has a Item 404(a) related-party transaction or selection arrangement requiring disclosure

19-10-2026

FrontView REIT, Inc. (FVR) disclosed that on October 15, 2026, its operating partnership entered into Amendment No. 5 to its Credit Agreement with JPMorgan Chase Bank, N.A. as administrative agent. The amendment extends the maturity of both the revolving credit facility and the term loans to October 3, 2028 and reduces certain interest rate margins, with pricing tied to leverage ratio before an investment-grade rating and to credit rating after one is obtained. The filing does not quantify the facility sizes or the magnitude of the margin reductions relative to prior terms.

• · Amendment No. 5 was entered into on October 15, 2026, and the 8-K was filed October 19, 2026
• · The full amendment will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026
• · The original Credit Agreement is dated September 6, 2024
• · Usage-based commitment fee on the Revolving Credit Facility was replaced with a facility fee
• · Ratings from S&P, Moody's or Fitch may be used for the ratings-based pricing grid
• · If leverage is 35% or less and a Baa2/BBB rating is obtained, Baa1/BBB+ pricing applies; a Baa3/BBB- rating triggers Baa2/BBB pricing
• · Certain lenders and agents and their affiliates have provided advisory, commercial and investment banking services to the company for customary fees

19-10-2026

JELD-WEN announced that CFO Samantha L. Stoddard will resign effective November 13, 2026, to pursue an opportunity outside the building products industry. Jeffrey Embt, Vice President and Chief Accounting Officer, will concurrently serve as Interim CFO while keeping his current role, and the company will begin a search for a permanent CFO. The company reaffirmed its updated full-year 2026 guidance of $3.1 billion to $3.2 billion in revenue and $120 million to $150 million in Adjusted EBITDA, as previously announced on August 3, 2026.

• · Stoddard's departure is effective November 13, 2026, the same date Embt assumes the Interim CFO role
• · Embt joined JELD-WEN in January 2026 and previously served as CFO and Chief Accounting Officer of Proterra LLC
• · Stoddard had served the company for six years
• · Guidance is a reaffirmation of ranges first set on August 3, 2026, and excludes potential acquisitions or divestitures

19-10-2026

Curis, Inc. (CRIS) entered into a Securities Purchase Agreement on October 16, 2026 for a private placement of 16,666,680 shares of common stock (or pre-funded warrants) and common warrants at an effective combined price of $0.51 per share, targeting gross proceeds of approximately $8.5 Million before placement agent fees and offering expenses. Proceeds are intended for research and development and working capital, and are expected to fund operations through initial Chronic Lymphocytic Leukemia (CLL) data in 5-10 patients in December 2026. The company also agreed to reduce the exercise price of certain January 2026 and August 2026 warrants to $0.60 per share, and to pay placement agents a 6.5% cash fee on gross proceeds.

• · Common Warrants expire April 19, 2032 and become exercisable six months after issuance
• · Liquidated damages of 1.0% per 30-day period apply if registration statement deadlines or effectiveness conditions are missed
• · Warrant holders may require repurchase at Black-Scholes value upon certain fundamental transactions not approved by the Board
• · Offering expected to close on or about October 19, 2026, subject to market conditions
• · Offering is a private placement under Section 4(a)(2) to accredited investors and qualified institutional buyers

19-10-2026

Lear Corporation announced a CFO succession plan under which Jared Fedele, currently Vice President of Finance for Seating and E-Systems, will become Senior Vice President and Chief Financial Officer effective March 1, 2027. Current CFO Jason Cardew, with 34 years of service, will remain CFO through February 28, 2027, then serve as non-executive Executive Advisor through December 31, 2027. The transition is presented as orderly and planned, with no financial results or performance metrics disclosed.

• · Fedele previously led Global Financial Planning and Analysis and held senior operational finance roles across Lear
• · Cardew will serve as non-executive Executive Advisor to senior management through December 31, 2027, supporting strategic matters
• · Fedele's Asia Pacific experience includes significant involvement supporting Lear's expansion in China
• · Ray Scott cited Fedele's role in leading the company's response to tariffs and profitability initiatives